Clinical Trials Logo

Clinical Trial Summary

The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 11C-M503. The goal of this radiotracer is to quantify alpha-synuclein that is abnormally deposited in the brain of people with Parkinson's disease (PD). Investigators will compare uptake in participants with PD versus participants with multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), as well as non-Parkinsonism volunteers. This multicenter project funded by an NIH U19 grant, is centered at U Pennsylvania (Penn, Grant PI: Robert Mach) in collaboration with U Pittsburgh (Pitt) (non-clinical site) Yale U, U of California at San Francisco (UCSF) and Washington University in St. Louis (WU). The University of Pennsylvania will act as the sIRB for this multi-center human subjects project and participants will be recruited from all sites.


Clinical Trial Description

The current protocol is to determine the biodistribution, metabolism, excretion and brain uptake of 11C-M503. The goal of this radiotracer is to quantify alpha-synuclein that is abnormally deposited in the brain of people with Parkinson's disease (PD). Investigators will compare uptake in participants with PD versus participants with multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), as well as non-Parkinsonism volunteers. This multicenter project funded by an NIH U19 grant, is centered at U Pennsylvania (Penn, Grant PI: Robert Mach) in collaboration with U Pittsburgh (Pitt) (non-clinical site) Yale U, U of California at San Francisco (UCSF) and Washington University in St. Louis (WU). The University of Pennsylvania will act as the sIRB for this multi-center human subjects project and participants will be recruited from all sites. Participating clinical sites will recruit up to 20 people with PD, 20 with MSA, 10 with PSP and 20 healthy controls across sites with all participants ranging from 40-85 years old. Investigators will encourage equal participation of males and females. This protocol will include up to 70 participants across all clinical sites (note that some of these participant scans performed at Penn may be used to calculate whole body biodistribution (BioD) and dosimetry. Investigators anticipate enrollment of up to 15-20 participants at each clinical site, who will undergo up to 120 minutes of dynamic brain PET scanning (with or without torso imaging, depending on the clinical site). A second IV or an arterial line may be placed, preferably in the arm contralateral to the side of injection, for blood metabolite analysis and/or radioactive counts at various times during the scanning session. These blood draw collections can be omitted at the discretion of the investigator. For participants at Penn that may be part of BioD analysis, urine may be collected at the end of the scan session. Participants will also undergo a research brain MRI that may be on a separate day from the PET. PET imaging sessions will include an injection of ≤ 15 mCi (approximate range for most studies is anticipated to be 8 - 15 mCi at sites with a standard PET scanner or 3 - 15 at sites with a high sensitivity scanner) of 11C-M503. Biodistribution, metabolism, excretion and pilot brain uptake data will be collected and human dosimetry will be calculated from participants scanned at Penn who have whole body scans. PET scans will be collected to evaluate image quality and collect preliminary information on brain uptake of 11C-M503 in the disease cohorts and healthy controls. The safety of 11C-M503 will also be evaluated in all participants. Some participants (usually those with positive 11C-M503 PET scan) may also be asked to have an amyloid-beta (Aβ) PET scan to investigate specificity of 11C-M503. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06303921
Study type Interventional
Source University of Pennsylvania
Contact Erin Schubert
Phone 215-662-3041
Email erinshu@pennmedicine.upenn.edu
Status Recruiting
Phase Early Phase 1
Start date February 16, 2024
Completion date February 2029

See also
  Status Clinical Trial Phase
Completed NCT05080777 - Pilot Pragmatic Clinical Trial to Embed Tele-Savvy Into Health Care Systems N/A
Completed NCT03538522 - A Double-Blind, Placebo-Controlled Safety and Efficacy Study of NA-831 Phase 2
Recruiting NCT05508789 - A Study of Donanemab (LY3002813) in Participants With Early Symptomatic Alzheimer's Disease (TRAILBLAZER-ALZ 5) Phase 3
Recruiting NCT05427448 - Validation of Blood Biomarkers for Alzheimer's Disease N/A
Active, not recruiting NCT05344989 - A First-in-Human Study to Assess Single Doses of APNmAb005 in Healthy Participants Phase 1
Recruiting NCT01696591 - The Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Completed the Phase I Clinical Trial of Neurostem®-AD N/A
Withdrawn NCT05321498 - Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation Phase 2
Completed NCT04445831 - A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease Phase 1/Phase 2
Recruiting NCT06083467 - CW2IP2: Imaging and Diagnostic Assessments Early Phase 1
Completed NCT05527288 - A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population N/A
Completed NCT02860338 - COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE N/A
Completed NCT05202223 - Harmony at Home: A Pilot Telehealth Program for Rural ADRD Caregivers N/A
Recruiting NCT05318976 - A Study of XPro1595 in Patients With Early Alzheimer's Disease With Biomarkers of Inflammation Phase 2
Active, not recruiting NCT05522387 - An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease Phase 2
Completed NCT02103894 - Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects Phase 1
Completed NCT02294851 - A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study of Intravenously Administered BMS-986168 in Healthy Subjects Phase 1
Recruiting NCT06032026 - Study of Biodistribution, Metabolism, Excretion and Brain Uptake of 11C-HY-2-15 Early Phase 1
Completed NCT03938870 - CNS Tau Kinetics in Healthy Aging and Alzheimer's Disease
Completed NCT02676843 - Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations Phase 2